Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 275

Posts Tagged ‘molecular’

Japan’s new molecular oncology clinical research

Posted by fidest press agency su giovedì, 20 giugno 2019

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAGEN Clinical Insight (QCI) offering was selected by the National Cancer Center of Japan, as part of the Japan’s Ministry of Health, Labour and Welfare’s precision medicine program, for the analysis, interpretation and reporting of molecular oncology and oncogenetic screening of cancer patients to contribute to the identification of targeted therapy treatment and clinical trial options.Japan’s Center for Cancer Genomics and Advanced Therapeutics (C-CAT), a unit within the National Cancer Center (NCC) of Japan, will use QIAGEN’s QCI platform including expert curated evidence knowledge bases, bioinformatics software and data center infrastructure to support the C-CAT’s molecular profiling services for core and cooperative hospitals of the country’s cancer genomic medicine program. QIAGEN has established an in-country data center in Tokyo, compliant with Japanese data security and privacy regulations, to support this national program.QCI is a cloud-based clinical decision support software platform used to generate actionable insights from next-generation sequencing (NGS) data. QCI leverages QIAGEN’s expert manually curated evidence knowledge base that includes more than 10 million biomedical findings and thereby be far represents the world’s largest commercial database of curated evidence data on somatic and inherited genetic variants. QCI-Interpret minimizes the complexity and cost of determining the significance of NGS data and automates guidelines for clinical actionability from leading oncology and pathology organizations.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Applied DNA’s Molecular Tagging Technology to Ensure Authenticity of Egyptian Cotton

Posted by fidest press agency su sabato, 4 maggio 2019

Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based manufacturing for product authenticity and traceability solutions, announced today it received an order for the implementation of its SigNature® T cotton traceability system in Egypt to indelibly mark two varietals of high-value Egyptian cotton, widely acknowledged to be among the finest in the world. The molecular tag and delivery system have been shipped and cotton tagging is expected to commence within the month. The system, already installed in eight cotton gins worldwide, includes the use of unique SigNature T molecular tags, internet-based data collection linking evidence of tagging process quality to each bale ID, and bar code scanning of tagged packaged bales for inventory management and tracking. The cotton fiber will be managed with strict protocols throughout the supply chain to ensure purity and traceability.“With receipt of this order for Egyptian cotton supply chain tagging and testing, we are moving to replicate our success in securing U.S. cotton through its supply chain. Given the uncertainty surrounding the provenance of Egyptian cotton in the marketplace and growing calls for increased transparency and traceability by consumers, brands and industry advocates, the implementation of our SigNature T cotton traceability system endeavors to ensure that the value of Egyptian cotton can be substantiated throughout its supply chain,” said Dr. James A. Hayward, president and CEO of Applied DNA.According to the Mundi Report, Egypt produced approximately 240 million pounds of cotton in the prior 2018 growing season, just below total U.S. Pima output.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

Posted by fidest press agency su sabato, 2 giugno 2018

Integral Molecular, the industry leader in membrane protein antibody discovery, announces the development of antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic syndrome (GLUT4 and CB1). These therapeutic assets are among the first released in a pipeline of antibodies being isolated with the MPS Discovery Engine®, which is tailored for the discovery of rare, functional antibodies against complex membrane protein targets.In a paper published in PNAS (Tucker et al., May 2018), the company revealed the discovery of the first functional MAbs against GLUT4, an insulin-responsive glucose transporter important in diabetes. Epitope mapping showed that MAbs LM043 and LM048 are rare state-specific MAbs, selectively binding only certain active forms of the GLUT4 transporter.Last month at the PEGS protein engineering conference, Integral Molecular presented their discovery of antagonist MAb IM-102 against CB1 for NASH (inflammatory liver disease). IM-102 inhibits CB1 with 23 times greater potency than a benchmark MAb currently in phase 1 clinical trials. At the AACR conference this spring, the company presented its discovery of highly specific antibodies against Claudin 6, an established membrane protein target in ovarian cancer.
Ross Chambers, VP of Antibody Discovery, attributes the company’s 95% success rate in MAb isolation to optimization of its antibody discovery platform: “Our proprietary technologies allow us to obtain hundreds of diverse, high-affinity antibodies against complex targets, enabling us to discover antibodies with rare functional properties.”Integral Molecular’s MPS Discovery Engine® encompasses a technology suite that overcomes the obstacles of working with highly homologous and structurally complex targets. This suite includes antigen engineering and presentation on Lipoparticles, immunization of divergent species, and use of B-cell cloning to recover rare antibodies. Integral Molecular is currently isolating MAbs against dozens of membrane protein targets.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Pavia: Erasmus Mundus

Posted by fidest press agency su mercoledì, 22 settembre 2010

Pavia 23 settembre 2010, ore 11,00 Sala del Consiglio, Rettorato dell’Università degli studi  si terrà un incontro, aperto alla stampa con i  primi 9 studenti provenienti dall’America Latina (Costa Rica, Colombia, Panama) che partecipano al progetto Erasmus Mundus dell’Università di Pavia. Si tratta di un progetto europeo grazie al quale studenti provenienti dall’America Latina, Colombia, Costa Rica e Panama, hanno l’opportunità di trascorrere un periodo tra i 6 e i 34 mesi all’Università di Pavia per frequentare i corsi di laurea di ingegneria, i corsi di laurea in lingua inglese in Molecular  Biology and Genetics e in International Business and Economics, oltre ai corsi di dottorato in varie discipline. A dare il benvenuto ai nuovi studenti sudamericani, il prof. Andrea Giuseppe Capodaglio, responsabile del progetto per l’Ateneo pavese che illustrerà il percorso didattico e le attività previste da Erasmus Mundus.

Posted in Cronaca/News, Università/University | Contrassegnato da tag: , , , | Leave a Comment »

Influenza: come il virus penetra nelle cellule

Posted by fidest press agency su giovedì, 13 agosto 2009

Scoperta la chiave usata dal virus dell’influenza stagionale per penetrare nelle cellule umane. Lo studio, firmato fra gli altri dai ricercatori dell’European Molecular Biology Laboratory e dell’Università Joseph Fournier (Francia), ha individuato importati obiettivi per nuovi farmaci anti-influenza. Nella ricerca, pubblicata su ‘Nature’, gli autori presentano un’immagine ad alta risoluzione di una parte di proteina cruciale, che permette al virus di penetrare nelle cellule umane e moltiplicarsi. Quando l’influenza infetta una cellula ospite, il suo obiettivo è quello di replicarsi il più possibile per andare all’attacco di altre cellule. Un enzima virale, chiamato polimerasi, è cruciale per questo processo, ma finora non era chiaro esattamente come la polimerasi agisse. I ricercatori del gruppo di Rob Ruigrok e Stephen Cusack hanno scoperto che parte di una subunità della polimerasi, chiamata PA, ha un ruolo fondamentale nel meccanismo di attacco messo in atto dal virus. Una tecnica che coinvolge le molecole di Rna dell’involontario ospite. Questi risultati aprono la strada a nuovi farmaci mirati: proprio il PA potrebbe diventare infatti un bersaglio promettente per nuovi antivirali. Agendo su questa parte della polimerasi, spiegano gli autori, si potrebbe bloccare l’infezione, perché il virus non sarebbe più in grado di moltiplicarsi.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »